A Phase 3 interventional study of Placebo and LX211 in Uveitis, Anterior and Panuveitis, sponsored by Lux Biosciences, Inc.. Completed at 30 sites in 7 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2012-06-22.
Sponsored by Lux Biosciences, Inc. · Phase 3, Interventional, and Treatment
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.
This study's enrollment of 108 is above the median of 50 across 45 interventional studies indexed under Uveitis, Anterior.
Browse Uveitis, Anterior studies →Lux Biosciences, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: LX211
Drug: LX211
Drug: LX211
anterior chamber cells
Time frame: 16 and 24 weeks
BCVA
Time frame: 24 weeks
macular thickness
Time frame: 16 and 24 weeks
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Lux Biosciences, Inc.